Latest News

Ceapro to Present at Biotech Showcase™ 2016 on January 12, 2016 – Presentation with live webcast on Tuesday, January 12th at 3:30 p.m. PT

EDMONTON, ALBERTA – January 5, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 8th Annual Biotech Showcase™ conference on

Read more

Ceapro Announces Issuance of Shares for Debt Reduction Initiative

EDMONTON, ALBERTA – December 24, 2015 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that pursuant to debt settlement agreements with each of its Directors, previously

Read more

Ceapro Strengthens Balance Sheet with Shares for Debt Reduction Initiative

EDMONTON, ALBERTA – December 3, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that pursuant to debt settlement agreements with each of its Directors, it

Read more

Ceapro Inc. Reports Third Quarter 2015 Financial Results and Provides Corporate Update – Company reports record sales with the highest quarterly revenue performance in its history – Company poised to fully leverage its proprietary enabling technologies to enter well established and growing markets

EDMONTON, ALBERTA – November 12, 2015 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30,

Read more

Ceapro Awarded Research Contribution from National Research Council of Canada for the Development, Demonstration and Testing of its Proprietary Pressurized Gas Expanded Technology (PGX) – Unique PGX enabling technology expected to generate novel bio-based products with improved purity and functionality in several industrial applications

EDMONTON, ALBERTA – November 12, 2015 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the National Research Council of Canada (NRC) through its Industrial Research

Read more

Ceapro Presents Unique Advantages of its Disruptive Pressurized Gas Expanded Technology (PGX) at 2015 Composites at Lake Louise

EDMONTON, ALBERTA – November 10, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced that Bernhard Seifried, Ph.D., Ceapro’s Senior Research Scientist and a co-inventor of its

Read more

Ceapro Inc. Reports Second Quarter 2015 Financial and Operations Results

EDMONTON, ALBERTA – August 26, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30,

Read more

Ceapro Presents Unique Advantages of Pressurized Gas Expanded Technology (PGX) at the 12th Annual BIO World Congress on Industrial Biotechnology

EDMONTON, ALBERTA – July 21, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, presented the unique advantages of its proprietary and novel Pressurized Gas eXpanded (PGX) platform

Read more

Ceapro to Present on Pressurized Gas Expanded Technology (PGX) at the 12th Annual BIO World Congress on Industrial Biotechnology – Co-inventor of PGX, Bernhard Seifried, Ph.D., to present on Ceapro’s platform technology for novel biopolymer applications

EDMONTON, ALBERTA – July 9, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that an abstract on its novel Pressurized Gas eXpanded (PGX) platform processing

Read more

Ceapro Featured at the 12th International Congress on Engineering and Food (ICEF12) – Gilles Gagnon, M.Sc., MBA, Ceapro’s President and CEO, Honorary Guest VIP Speaker at the ICEF opening ceremony – Bernhard Seifried, Ph.D., Senior Research Scientist and co-inventor of Ceapro’s PGX Technology to present on June 17, 2015

EDMONTON, ALBERTA – June 15, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced its featured participation in the 12th International Congress on Engineering and Food (ICEF12)

Read more
Page 3 of 1012345...10...Last »